Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on October 1, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Aziz Sawaf becomes Vir’s permanent CFO and principal financial officer October 5, replacing interim CFO Brent Sabatini.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Aziz Sawaf becomes Vir’s permanent CFO and principal financial officer October 5, replacing interim CFO Brent Sabatini
- Sawaf brings CFO experience at Theravance and prior Gilead finance experience, strengthening biotech financial leadership
- Compensation includes $520,000 base salary, 45% target bonus, and $150,000 sign-on bonus
- Equity package includes options on 150,000 shares and RSUs covering 75,000 shares, vesting over four years
- Severance includes nine months’ salary outside a change in control and 12 months’ salary plus target bonus during one year afterward
Item 7.01 · Regulation FD Disclosure
- Appointment of Mr. Sawaf as Executive Vice President and Chief Financial Officer
- CFO transition potentially affecting financial reporting, capital allocation, and investor communications
- Press release issued October 1, 2026; additional appointment details in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.